{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:25:49Z","timestamp":1769811949215,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7759\/cureus.102618","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:20:26Z","timestamp":1769768426000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors on Lipid Profiles in Type 2 Diabetes: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Mushrega","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mudathir Elyas Suleiman","family":"Khamees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed-Lamin","family":"Gehani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abubaker Ibrahim Mohammed","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muntassir  Y","family":"Yousif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Kheir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safa","family":"Mohammed Qasem Alqasem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun H","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, et al.. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022, 183:109119. 10.1016\/j.diabres.2021.109119","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review","volume":"15","author":"Seidu S","year":"2024","unstructured":"Seidu S, Alabraba V, Davies S, et al.. SGLT2 inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review. Diabetes Ther. 2024, 15:1099-124. 10.1007\/s13300-024-01550-5","journal-title":"Diabetes Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.3.7304","article-title":"Diabetic dyslipidemia: causes and consequences","volume":"86","author":"Goldberg IJ","year":"2001","unstructured":"Goldberg IJ. Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab. 2001, 86:965-71. 10.1210\/jcem.86.3.7304","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini E","year":"2012","unstructured":"Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012, 8:495-502. 10.1038\/nrendo.2011.243","journal-title":"Nat Rev Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal B","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al.. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017, 377:644-57. 10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott SD","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al.. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019, 380:347-57. 10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000188034.76283.5e","article-title":"Management of dyslipidemia in diabetes","volume":"14","author":"Solano MP","year":"2006","unstructured":"Solano MP, Goldberg RB. Management of dyslipidemia in diabetes. Cardiol Rev. 2006, 14:125-35. 10.1097\/01.crd.0000188034.76283.5e","journal-title":"Cardiol Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166125","article-title":"Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Storgaard H","year":"2016","unstructured":"Storgaard H, Gluud LL, Bennett C, Gr\u00f8ndahl MF, Christensen MB, Knop FK, Vilsb\u00f8ll T. Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS One. 2016, 11:e0166125. 10.1371\/journal.pone.0166125","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"S\u00e1nchez-Garc\u00eda A","year":"2020","unstructured":"S\u00e1nchez-Garc\u00eda A, Simental-Mend\u00eda M, Mill\u00e1n-Alan\u00eds JM, Simental-Mend\u00eda LE. Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials. Pharmacol Res. 2020, 160:105068. 10.1016\/j.phrs.2020.105068","journal-title":"Pharmacol Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216544","article-title":"Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu","volume":"11","author":"Yaribeygi H","year":"2022","unstructured":"Yaribeygi H, Maleki M, Reiner \u017d, Jamialahmadi T, Sahebkar A. Mechanistic view on the effects of SGLT2 inhibitors on lipid metabolism in diabetic milieu. J Clin Med. 2022, 11:6544. 10.3390\/jcm11216544","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00086.2017","article-title":"Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes","volume":"313","author":"Tang L","year":"2017","unstructured":"Tang L, Wu Y, Tian M, et al.. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab. 2017, 313:E563-76. 10.1152\/ajpendo.00086.2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl S","year":"2020","unstructured":"Kahl S, Gancheva S, Stra\u00dfburger K, et al.. Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. Diabetes Care. 2020, 43:298-305. 10.2337\/dc19-0641","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0558","article-title":"Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes","volume":"11","author":"Lauritsen KM","year":"2022","unstructured":"Lauritsen KM, Voigt JH, Pedersen SB, et al.. Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes. Endocr Connect. 2022, 11:e210558. 10.1530\/EC-21-0558","journal-title":"Endocr Connect"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0529-3","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial","volume":"16","author":"Fadini GP","year":"2017","unstructured":"Fadini GP, Bonora BM, Zatti G, et al.. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017, 16:42. 10.1186\/s12933-017-0529-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0491-5","article-title":"Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin","volume":"16","author":"Hayashi T","year":"2017","unstructured":"Hayashi T, Fukui T, Nakanishi N, et al.. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol. 2017, 16:8. 10.1186\/s12933-016-0491-5","journal-title":"Cardiovasc Diabetol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman B","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al.. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015, 373:2117-28. 10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02916-0","article-title":"Effect of empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial","volume":"24","author":"Bauer KI","year":"2025","unstructured":"Bauer KI, Baker D, Lerner R, et al.. Effect of empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial. Cardiovasc Diabetol. 2025, 24:359. 10.1186\/s12933-025-02916-0","journal-title":"Cardiovasc Diabetol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2024.12.015","article-title":"Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE","volume":"19","author":"Emanuelsson F","year":"2025","unstructured":"Emanuelsson F, Jensen J, Omar M, et al.. Effect of empagliflozin on plasma lipids and lipoproteins in type 2 diabetes and heart failure - Empire HF and SIMPLE. J Clin Lipidol. 2025, 19:276-85. 10.1016\/j.jacl.2024.12.015","journal-title":"J Clin Lipidol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.01.018","article-title":"Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels","volume":"11","author":"Bays HE","year":"2017","unstructured":"Bays HE, Sartipy P, Xu J, Sj\u00f6str\u00f6m CD, Underberg JA. Dapagliflozin in patients with type II diabetes mellitus, with and without elevated triglyceride and reduced high-density lipoprotein cholesterol levels. J Clin Lipidol. 2017, 11:450-8.e1. 10.1016\/j.jacl.2017.01.018","journal-title":"J Clin Lipidol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001083","article-title":"Effect of canagliflozin compared with sitagliptin on serum lipids in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction: a post-hoc analysis of the CANA-HF study","volume":"78","author":"Dixon DL","year":"2021","unstructured":"Dixon DL, Billingsley HE, Canada JM, et al.. Effect of canagliflozin compared with sitagliptin on serum lipids in patients with type 2 diabetes mellitus and heart failure with reduced ejection fraction: a post-hoc analysis of the CANA-HF study. J Cardiovasc Pharmacol. 2021, 78:407-10. 10.1097\/FJC.0000000000001083","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/2431441","article-title":"The effect of canagliflozin on high-density lipoprotein cholesterol and angiopoietin-like protein 3 in type 2 diabetes mellitus","volume":"2024","author":"Liu S","year":"2024","unstructured":"Liu S, Ke J, Feng X, Wang Z, Wang X, Yang L, Zhao D. The effect of canagliflozin on high-density lipoprotein cholesterol and angiopoietin-like protein 3 in type 2 diabetes mellitus. J Diabetes Res. 2024, 2024:2431441. 10.1155\/2024\/2431441","journal-title":"J Diabetes Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01228-3","article-title":"A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study","volume":"20","author":"Hiruma S","year":"2021","unstructured":"Hiruma S, Shigiyama F, Hisatake S, et al.. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021, 20:32. 10.1186\/s12933-021-01228-3","journal-title":"Cardiovasc Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-1270","article-title":"Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus","volume":"186","author":"Burggraaf B","year":"2022","unstructured":"Burggraaf B, Pouw NM, Fern\u00e1ndez Arroyo S, et al.. Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus. Eur J Endocrinol. 2022, 186:597-605. 10.1530\/EJE-21-1270","journal-title":"Eur J Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.37762\/jgmds.9-3.174","article-title":"Evaluating impact of empagliflozin on lipid profile of patients of type 2 diabetes mellitus","volume":"9","author":"Wazir N","year":"2022","unstructured":"Wazir N, Rehman S. Evaluating impact of empagliflozin on lipid profile of patients of type 2 diabetes mellitus. J Gandhara Med Dent Sci. 2022, 9:20-4. 10.37762\/jgmds.9-3.174","journal-title":"J Gandhara Med Dent Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2021.01.063","article-title":"Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: association with a slight increase in high-density lipoprotein cholesterol","volume":"331","author":"Jojima T","year":"2021","unstructured":"Jojima T, Sakurai S, Wakamatsu S, et al.. Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: association with a slight increase in high-density lipoprotein cholesterol. Int J Cardiol. 2021, 331:243-8. 10.1016\/j.ijcard.2021.01.063","journal-title":"Int J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.59049\/2790-0231.10.4.2410","article-title":"Role of dapagliflozin versus empagliflozin as add-on therapy on diabetic nephropathy","volume":"10","author":"Najim HD","year":"2025","unstructured":"Najim HD, Mohammed MM, Rahmah AM. Role of dapagliflozin versus empagliflozin as add-on therapy on diabetic nephropathy. Pal Med Pharm J. 2025, 10:373-8. 10.59049\/2790-0231.10.4.2410","journal-title":"Pal Med Pharm J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1542741","article-title":"Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial","volume":"12","author":"Fukada H","year":"2025","unstructured":"Fukada H, Kon K, Yaginuma R, et al.. Effectiveness and risks of dapagliflozin in treatment for metabolic dysfunction-associated steatotic liver disease with type 2 diabetes: a randomized controlled trial. Front Med (Lausanne). 2025, 12:1542741. 10.3389\/fmed.2025.1542741","journal-title":"Front Med (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/1479164120975256","article-title":"Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME\u00ae","volume":"17","author":"Langslet G","year":"2020","unstructured":"Langslet G, Zinman B, Wanner C, Hantel S, Espadero RM, Fitchett D, Johansen OE. Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME\u00ae. Diab Vasc Dis Res. 2020, 17:1479164120975256. 10.1177\/1479164120975256","journal-title":"Diab Vasc Dis Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1161\/circ.144.suppl_1.13182","article-title":"Dapagliflozin and changes in metabolic syndrome in patients with type 2 diabetes: a DECLARE TIMI 58 sub-analysis","volume":"144","author":"Moura FA","year":"2021","unstructured":"Moura FA, Raz I, Cahn A, et al.. Dapagliflozin and changes in metabolic syndrome in patients with type 2 diabetes: a DECLARE TIMI 58 sub-analysis. Circulation. 2021, 144:13182. 10.1161\/circ.144.suppl_1.13182","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1530\/EC-25-0219","article-title":"Long-term efficacy of dapagliflozin combined with Bifidobacterium triple viable tablets on metabolic syndrome and gut microbiota in overweight\/obese patients with type 2 diabetes","volume":"14","author":"Li K","year":"2025","unstructured":"Li K, Li Z, Liu L. Long-term efficacy of dapagliflozin combined with Bifidobacterium triple viable tablets on metabolic syndrome and gut microbiota in overweight\/obese patients with type 2 diabetes. Endocr Connect. 2025, 14:e250219. 10.1530\/EC-25-0219","journal-title":"Endocr Connect"},{"key":"ref34","article-title":"Effect of dapagliflozin on lipid profile in type-2 diabetes mellitus","volume":"14","author":"Kabir W","year":"2023","unstructured":"Kabir W, Khan AU, Gul F, Qadir M. Effect of dapagliflozin on lipid profile in type-2 diabetes mellitus. J Pharm Negat Results. 2023, 14:644-50.","journal-title":"J Pharm Negat Results"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02149-7","article-title":"Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study","volume":"23","author":"Nagao M","year":"2024","unstructured":"Nagao M, Sasaki J, Tanimura-Inagaki K, Sakuma I, Sugihara H, Oikawa S. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study. Cardiovasc Diabetol. 2024, 23:56. 10.1186\/s12933-024-02149-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.06.915","article-title":"Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"330","author":"Rau M","year":"2021","unstructured":"Rau M, Thiele K, Korbinian Hartmann NU, et al.. Effects of empagliflozin on lipoprotein subfractions in patients with type 2 diabetes: data from a randomized, placebo-controlled study. Atherosclerosis. 2021, 330:8-13. 10.1016\/j.atherosclerosis.2021.06.915","journal-title":"Atherosclerosis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19371-6","article-title":"Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure","volume":"12","author":"Ejiri K","year":"2022","unstructured":"Ejiri K, Miyoshi T, Kihara H, et al.. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure. Sci Rep. 2022, 12:15449. 10.1038\/s41598-022-19371-6","journal-title":"Sci Rep"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/1179551419866811","article-title":"Potential impact on lipoprotein subfractions in type 2 diabetes","volume":"12","author":"Kamijo Y","year":"2019","unstructured":"Kamijo Y, Ishii H, Yamamoto T, et al.. Potential impact on lipoprotein subfractions in type 2 diabetes. Clin Med Insights Endocrinol Diabetes. 2019, 12:1179551419866811. 10.1177\/1179551419866811","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.48176\/esmj.2023.108","article-title":"Effect of sodium glucose co-transporter 2 inhibitors on lipid levels in newly diagnosed hypertensive patients with type 2 diabetes mellitus","volume":"4","author":"Do\u011fanay B","year":"2023","unstructured":"Do\u011fanay B, Celebi OO. Effect of sodium glucose co-transporter 2 inhibitors on lipid levels in newly diagnosed hypertensive patients with type 2 diabetes mellitus. Eskisehir Med J. 2023, 4:73-9. 10.48176\/esmj.2023.108","journal-title":"Eskisehir Med J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109123","article-title":"Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study","volume":"182","author":"Ku EJ","year":"2021","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Res Clin Pract. 2021, 182:109123. 10.1016\/j.diabres.2021.109123","journal-title":"Diabetes Res Clin Pract"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108541","article-title":"Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: a prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease","volume":"37","author":"Grubi\u0107 Rotkvi\u0107 P","year":"2023","unstructured":"Grubi\u0107 Rotkvi\u0107 P, \u0106elap I, Brali\u0107 Lang V, Jug J, Snagi\u0107 A, Huljev \u0160ipo\u0161 I, Cigrovski Berkovi\u0107 M. Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: a prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease. J Diabetes Complications. 2023, 37:108541. 10.1016\/j.jdiacomp.2023.108541","journal-title":"J Diabetes Complications"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.89091","article-title":"Effects of dapagliflozin vs. vildagliptin on the lipid profile of patients with uncontrolled type 2 diabetes","volume":"17","author":"Khanna S","year":"2025","unstructured":"Khanna S, Malik M, Ahmad R. Effects of dapagliflozin vs. vildagliptin on the lipid profile of patients with uncontrolled type 2 diabetes. Cureus. 2025, 17:e89091. 10.7759\/cureus.89091","journal-title":"Cureus"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0269414","article-title":"Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease","volume":"17","author":"Lim J","year":"2022","unstructured":"Lim J, Hwang IC, Choi HM, Yoon YE, Cho GY. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease. PLoS One. 2022, 17:e0269414. 10.1371\/journal.pone.0269414","journal-title":"PLoS One"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/17446651.2025.2550733","article-title":"Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial","volume":"20","author":"Pahlavan Y","year":"2025","unstructured":"Pahlavan Y, Ramezani M, Mirmohammadkhani M, Sathyapalan T, Ziari A, Yaribeygi H. Adding empagliflozin to ongoing metformin improves metabolic profile, tg-g and fib-4 indexes and liver function tests in type 2 diabetic patients with NAFLDS, a clinical trial. Expert Rev Endocrinol Metab. 2025, 20:633-41. 10.1080\/17446651.2025.2550733","journal-title":"Expert Rev Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.163923.3","article-title":"Dapagliflozin vs. empagliflozin for cardiorenal risk reduction: real-world paired data and comparative study in Indonesia","volume":"14","author":"Cokro F","year":"2025","unstructured":"Cokro F, Sauriasari R, Tahapary DL, Setiawan H, Tricaesario C, Hidayati N, Soegondo S. Dapagliflozin vs. empagliflozin for cardiorenal risk reduction: real-world paired data and comparative study in Indonesia. F1000Res. 2025, 14:569. 10.12688\/f1000research.163923.3","journal-title":"F1000Res"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.31550\/1727-2378-2023-22-4-40-46","article-title":"[Effect of dapagliflozin on fat and carbohydrate metabolism in patients with type 2 diabetes mellitus]","volume":"22","author":"Gogoleva S","year":"2023","unstructured":"Gogoleva S, Ametov A, Shabalina A. [Effect of dapagliflozin on fat and carbohydrate metabolism in patients with type 2 diabetes mellitus]. Doctor Ru. 2023, 22:40-6. 10.31550\/1727-2378-2023-22-4-40-46","journal-title":"Doctor Ru"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024593","article-title":"Effect of SGLT inhibitors on weight and lipid metabolism at 24\u200aweeks of treatment in patients with diabetes mellitus: a systematic review and network meta-analysis","volume":"100","author":"Chen MB","year":"2021","unstructured":"Chen MB, Wang H, Cui WY, Xu HL, Zheng QH. Effect of SGLT inhibitors on weight and lipid metabolism at 24\u200aweeks of treatment in patients with diabetes mellitus: a systematic review and network meta-analysis. Medicine (Baltimore). 2021, 100:e24593. 10.1097\/MD.0000000000024593","journal-title":"Medicine (Baltimore)"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0640-4","article-title":"Rationale, design for the ASSET study: a prospective randomized study comparing empagliflozin\u2019s effect to sitagliptin on cardiac fat accumulation\/function in patients with type 2 diabetes","volume":"10","author":"Shigiyama F","year":"2019","unstructured":"Shigiyama F, Hiruma S, Hisatake S, Shiraga N, Ikeda T, Hirose T, Kumashiro N. Rationale, design for the ASSET study: a prospective randomized study comparing empagliflozin\u2019s effect to sitagliptin on cardiac fat accumulation\/function in patients with type 2 diabetes. Diabetes Ther. 2019, 10:1509-21. 10.1007\/s13300-019-0640-4","journal-title":"Diabetes Ther"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0730-z","article-title":"Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study","volume":"17","author":"Shigiyama F","year":"2018","unstructured":"Shigiyama F, Kumashiro N, Fuchigami A, Hirose T. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study. Cardiovasc Diabetol. 2018, 17:86. 10.1186\/s12933-018-0730-z","journal-title":"Cardiovasc Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/438849-effects-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-on-lipid-profiles-in-type-2-diabetes-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T10:20:26Z","timestamp":1769768426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/438849-effects-of-sodium-glucose-cotransporter-2-sglt2-inhibitors-on-lipid-profiles-in-type-2-diabetes-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.102618","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,30]]}}}